Treatment and prevention practices in postmenopausal women after bone mineral density screening at a community-based osteoporosis project

Journal of the American Osteopathic Association

Volumn 106, Issue 7, 2006, Pages 396-401

  Rohr, Christine I ^a   Clements, John M ^a,b   Sarkar, Arup ^a  

^a Synergy Medical Education Alliance ^*  (United States)

^b Research and Educational Programs   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCITONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ARTICLE; BONE DENSITY; COMMUNITY BASED REHABILITATION; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; EXERCISE; FEMALE; FOLLOW UP; HEALTH SURVEY; HUMAN; INTERVIEW; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE; SCORING SYSTEM; SCREENING;

AGED; AGED, 80 AND OVER; CALCIUM; DENSITOMETRY, X-RAY; FEMALE; FOLLOW-UP STUDIES; HEALTH BEHAVIOR; HUMANS; INTERVIEWS; MASS SCREENING; MICHIGAN; MIDDLE AGED; OSTEOPOROSIS;

EID: 33747496014     PISSN: 00986151     EISSN: 00986151     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Cranney A, Welch V, Tugwell P, Wells G, Adachi JD, McGowan J, et al. Responsiveness of endpoints in osteoporosis clinical trials - an update. J Rheumatol. 1999;26:222-228.
2. National Osteoporosis Foundation Web site. Prevention: who's at risk? 2002. Available at: http://www.nof.org/prevention/risk.htm. Accessed April 17, 2006.
3. Rubin MR, Bilezikian JP. New anabolic therapies in osteoporosis. Curr Opin Rheumatol. 2002:14:433-440.
4. Greenspan SL, Schneider DL, McClung MR, Miller PD, Schnitzer TJ, Bonin R, et al. Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002;136:742-746.
5. Johnell O, Scheel WH, Lu Y, Reginster JY, Need AG, Seeman E. Additive effects of raloxifene and alendronate on BMD and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002;87:985-992.
6. Duncan CS, Blimkie CJ, Cowell CT, Burke ST, Briody JN, Howman-Giles R. Bone mineral density in adolescent female athletes: relationship to exercise type and muscle strength. Med Sci Sports Exerc. 2002;34:286-294.
7. Blanchet C, Giguere Y, Prud'homme D, Dumont M, Rousseau F, Dodin S. Association of physical activity and bone: influence of vitamin D receptor genotype. Med Sci Sports Exerc. 2002;34:24-31.
8. Weaver CM, Teegarden D, Lyle RM, McCabe GP, McCabe LD, Proulx W, et al. Impact of exercise on bone health and contraindication of oral contraceptive use in young women. Med Sci Sports Exerc. 2001;33:873-880.
9. Rohr CI, Sarkar A, Barber KR, Clements JM. Prevalence of prevention and treatment modalities used in populations at risk of osteoporosis. J Am Osteopath Assoc. 2004;104:281-287. Available at: http://www.jaoa.org/cgi/content/ abstract/104/7/281. Accessed April 17, 2006.
10. Siris ES, Bilezikian JP, Rubin MR, Black DM, Bockman RS, Bone HG, et al. Pins and plaster aren't enough: a call for the evaluation and treatment of patients with osteoprotic fractures. J Clin Endocrinol Metab. 2003;88:3482-3486.
11. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. Geneva, Switzerland: World Health Organization; 1994. WHO Technical Report Series, No. 843.
12. Gambacciani M, Ciaponi M, Cappagli B, Genazzani AR. Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women. Am J Obstet Gynecol. 2001;185:1180-1185.
13. Harris ST, Eriksen EF, Davidson M, Ettinger MP, Moffett AH Jr, Baylink DJ, et al. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab. 2001;86:1890-1897.
14. Villareal DT, Binder EF, Williams DB, Schechtman KB, Yarasheski KE, Kohrt WM. Bone mineral density response to estrogen replacement in frail elderly women: a randomized controlled trial. JAMA. 2001;286:815-820.
15. Mosca L, Collins P, Herrington DM, Mendelsohn ME, Pasternak RC, Robertson RM, et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 2001;104:499-503.
16. Andrade SE, Majumdar SR, Chan KA, Buist DS, Go AS, Goodman M, et al. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med. 2003;163:2052-2057.
17. Malik R. Prevalence of osteoporosis treatment in hip fracture patients [abstract]. J Am Geriatr Soc. 2003;51(suppl 4):227-237.
18. Hsieh C, Novielli KD, Diamond JJ, Cheruva D. Health beliefs and attitudes toward the prevention of osteoporosis in older women. Menopause. 2001;8:372-376.
19. Ryan PJ, Harrison R, Blake GM, Fogelman I. Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis. Br J Obstet Gynaecol. 1992;99:325-328.
20. Torgerson DJ, Thomas RE, Campbell MK, Reid DM. Randomized trial of osteoporosis screening: use of hormone replacement therapy and quality-of-life results. Arch Intern Med. 1997;157:2121-2125.
21. Papaioannou A, Parkinson W, Adachi J, O'Connor A, Jolly EE, Tugwell P, et al. Women's decisions about hormone replacement therapy after education and bone densitometry. CMAJ. 1998;159:1253-1257.
22. Fitt NS, Mitchell SL, Cranney A, Gulenchyn K, Huang M, Tugwell P. Influence of bone densitometry results on the treatment of osteoporosis. CMAJ. 2001;164:777-781.